These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19027488)

  • 21. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas.
    Toyooka KO; Toyooka S; Virmani AK; Sathyanarayana UG; Euhus DM; Gilcrease M; Minna JD; Gazdar AF
    Cancer Res; 2001 Jun; 61(11):4556-60. PubMed ID: 11389090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.
    Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Ishizuka T; Saito R; Nakajima T; Mori M
    Int J Oncol; 2007 Jul; 31(1):169-73. PubMed ID: 17549418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic inactivation of the thyroid hormone receptor beta1 gene at 3p24.2 in lung cancer.
    Iwasaki Y; Sunaga N; Tomizawa Y; Imai H; Iijima H; Yanagitani N; Horiguchi K; Yamada M; Mori M
    Ann Surg Oncol; 2010 Aug; 17(8):2222-8. PubMed ID: 20155399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
    Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
    Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylated +322-327 CpG site decreases hOGG1 mRNA expression in non-small cell lung cancer.
    Zeng Y; Zhu J; Qin H; Shen D; Lei Z; Li W; Ding Z; Huang JA; Liu Z
    Oncol Rep; 2017 Jul; 38(1):529-537. PubMed ID: 28586012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation.
    Zöchbauer-Müller S; Fong KM; Geradts J; Xu X; Seidl S; End-Pfützenreuter A; Lang G; Heller G; Zielinski CC; Gazdar AF; Minna JD
    Oncogene; 2005 Sep; 24(41):6249-55. PubMed ID: 15940253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aberrant methylation of N-methyl-D-aspartate receptor type 2B (NMDAR2B) in non-small cell carcinoma.
    Tamura H; Suzuki M; Moriya Y; Hoshino H; Okamoto T; Yoshida S; Yoshino I
    BMC Cancer; 2011 Jun; 11():220. PubMed ID: 21639937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic Suppression of the T-box Subfamily 2 (
    Nehme E; Rahal Z; Sinjab A; Khalil A; Chami H; Nemer G; Kadara H
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
    Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
    Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
    Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
    Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer.
    Yu J; Bulk E; Ji P; Hascher A; Tang M; Metzger R; Marra A; Serve H; Berdel WE; Wiewroth R; Koschmieder S; Müller-Tidow C
    Clin Cancer Res; 2010 Apr; 16(8):2275-83. PubMed ID: 20371680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The expression of ADAM23 and its correlation with promoter methylation in non-small-cell lung carcinoma.
    Hu C; Lv H; Pan G; Cao H; Deng Z; Hu C; Wen J; Zhou J
    Int J Exp Pathol; 2011 Oct; 92(5):333-9. PubMed ID: 21429053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
    Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
    Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features.
    Kim DS; Kim MJ; Lee JY; Lee SM; Choi JY; Yoon GS; Na YK; Hong HS; Kim SG; Choi JE; Lee SY; Park JY
    Mol Carcinog; 2009 Dec; 48(12):1109-15. PubMed ID: 19554572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma.
    Kim JS; Han J; Shim YM; Park J; Kim DH
    Cancer; 2005 Nov; 104(9):1825-33. PubMed ID: 16177988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
    Zhong S; Fields CR; Su N; Pan YX; Robertson KD
    Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Critical role of deltaDNMT3B4/2 in regulating RASSF1A promoter-specific DNA methylation in non-small cell lung cancer.
    Wang SH; Liu NH; Wang J; Bai H; Mao L
    Chin Med J (Engl); 2008 Sep; 121(17):1712-21. PubMed ID: 19024105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Promoter methylation of ASPP1 and ASPP2 genes in non-small cell lung cancers].
    Wei WL; Hu HY; Zhang LJ; Chen Y; Ye E; Wang XF
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):532-6. PubMed ID: 22169642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methylation-mediated loss of SFRP2 enhances invasiveness of non-small cell lung cancer cells.
    Zhang X; Rong X; Chen Y; Su L
    Hum Exp Toxicol; 2018 Feb; 37(2):155-162. PubMed ID: 29320940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased expression of connective tissue growth factor in non-small cell lung cancer is associated with clinicopathological variables and can be restored by epigenetic modifiers.
    Drzewiecka H; Gałęcki B; Jarmołowska-Jurczyszyn D; Kluk A; Dyszkiewicz W; Jagodziński PP
    J Cancer Res Clin Oncol; 2016 Sep; 142(9):1927-46. PubMed ID: 27393180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.